Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 31 July 2013 | By Alexander Gaffney, RAC,
An Untitled Letter sent to Spectrum Pharmaceuticals by the US Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) cited an advertisement used to market the company's non-Hodkin's lymphoma drug Zevalin, which regulators claim over-states the drug's efficacy.
Per FDA regulations, all advertisements for approved pharmaceuticals must meet certain basic standards, among them an appropriate and accurate representation of the drug's risks and benefits, both balanced in equal measure against one another.
OPDP routinely sends out Untitled and Warning Letters to companies that fail to ensure the accuracy of their advertisements, particularly when those claims are published in lengthy sales aids intended to be read by prescribing professionals with responsibility for a patient's well-being.
And if there's one thing that comes across in these Untitled Letters, it's that OPDP reads these sales aids closely-very, very closely.
And a close reading of Spectrum Pharmaceutical's sales aid turned out to be bad news for the company, according to the Untitled Letter, which was posted to FDA's website on 31 July 2013.
OPDP said it took issue with the company's claim that Zevalin "delivers radiation precisely where it's needed" and that the product "specifically targets" an antigen found in most B-cell lymphomas. Those claims were based off a Phase I/II study that was not intended to determine either claim, and accordingly did not meet FDA's standards of evidence.
In addition, the company wrote in the sales aid that side effects can be "predictable and manageable," a claim FDA said minimizes the "serious risks" associated with the product's use.
Other parts of the same sales aid reportedly had the effect of over-stating the product's efficacy, noting that use of the drug was tied to "improved overall survival" and "improved long-term survival." OPDP said the precise wording of both claims were not supported by data reviewed by agency regulators. Similar violations were noted in six other claims, FDA added.
Unfortunately for Spectrum, OPDP said it had reason to read the company's materials more closely, having already sent "advisory comments" to the company in 2003, 2004 (twice), 2006 and 2009, with several of these letters speaking to alleged mischaracterizations of the respective product's mechanism of action and associated risks.
FDA said it had requested that Spectrum cease marketing Zevalin using the cited material and to submit a written response by 6 August 2013.
Untitled Letter to Spectrum
Sales Aid
Tags: OPDP, Untitled Letter
Regulatory Focus newsletters
All the biggest regulatory news and happenings.